| 000 | 01010 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250513134608.0 | ||
| 264 | 0 | _c19980311 | |
| 008 | 199803s 0 0 eng d | ||
| 022 | _a0114-5916 | ||
| 024 | 7 |
_a10.2165/00002018-199818010-00004 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPerez, E A | |
| 245 | 0 | 0 |
_aA risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis. _h[electronic resource] |
| 260 |
_bDrug safety _cJan 1998 |
||
| 300 |
_a43-56 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntiemetics _xeconomics |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aCost of Illness |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 |
_aSerotonin Antagonists _xeconomics |
| 650 | 0 | 4 |
_aVomiting _xchemically induced |
| 773 | 0 |
_tDrug safety _gvol. 18 _gno. 1 _gp. 43-56 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/00002018-199818010-00004 _zAvailable from publisher's website |
| 999 |
_c9435050 _d9435050 |
||